Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 5/2011

01.05.2011 | Original Article

The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model

verfasst von: Tamar Tadmor, Yu Zhang, Hyun-Mi Cho, Eckhard R. Podack, Joseph D. Rosenblatt

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Increasing evidence suggests that B lymphocytes play a central role in inhibiting the immune response against certain tumors, but the underlying mechanisms by which B cells facilitate tumor growth are still poorly understood. In this study, we investigated how the presence or absence of B cells affects expansion and function of T-regulatory cells (‘T-regs’) in a murine breast tumor model (EMT-6). We compared tumor growth, and the number and function of T-reg cells in wild-type immune-competent mice (ICM) and B-cell-deficient mice (BCDM). Mice were either tumor-naive or implanted with EMT-6 mammary adenocarcinoma cells. Tumor growth was markedly inhibited in BCDM, compared to wild-type mice (ICM). Increased T-reg expansion as defined by CD4+/CD25+/FOXP3+ cells was evident following EMT-6 inoculation in ICM in comparison with non-tumor-bearing mice or compared to BCDM in which tumor had been implanted. The percentage and absolute number of T-regs in the spleen, tumor draining lymph nodes, and tumor bed were significantly reduced in BCDM compared to ICM. T-reg function, measured by suppression and proliferation assays, was also reduced in tumor inoculated BCDM compared to ICM. Our studies indicate that absence of B cells may play a role in augmenting the T-cell anti-tumor response, in part due to effects on T-regulatory cell expansion and function.
Literatur
1.
Zurück zum Zitat LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112(5):1570–1580 LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112(5):1570–1580
2.
Zurück zum Zitat Shah S, Divekar AA, Hilchey SP et al (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells Int J Cancer 117(4):574–586 Shah S, Divekar AA, Hilchey SP et al (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells Int J Cancer 117(4):574–586
3.
Zurück zum Zitat Inoue S, Leitner W, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66:7741–7747 Inoue S, Leitner W, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66:7741–7747
4.
Zurück zum Zitat Brodt P, Gordon J (1978) Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol. 121(1):359-62 Brodt P, Gordon J (1978) Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol. 121(1):359-62
5.
Zurück zum Zitat Zhou G, Levitsky HI (2007) Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 178:2155–2162PubMed Zhou G, Levitsky HI (2007) Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 178:2155–2162PubMed
6.
Zurück zum Zitat Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108(3):804–811 Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108(3):804–811
7.
Zurück zum Zitat Reichardt P, Dornbach B, Rong S et al (2007) Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 110(5):1519–1529 PubMedCrossRef Reichardt P, Dornbach B, Rong S et al (2007) Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 110(5):1519–1529 PubMedCrossRef
8.
Zurück zum Zitat Chen X, Jensen PE (2007) Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J Immunol 179:2046–2050 Chen X, Jensen PE (2007) Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J Immunol 179:2046–2050
9.
Zurück zum Zitat Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG (2001) B cells, professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2(12):1126–1132PubMedCrossRef Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG (2001) B cells, professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2(12):1126–1132PubMedCrossRef
10.
Zurück zum Zitat Knoechel B, Lohr J, Kahn E, Abbas AK (2005) The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J Immunol 175(1):21–26 Knoechel B, Lohr J, Kahn E, Abbas AK (2005) The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J Immunol 175(1):21–26
11.
Zurück zum Zitat Levings MK, Sangregorio R, Roncarolo MG (2001) Human Cd25+ Cd4+ T Regulatory cells suppress naive and memory T Cell Proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295–1302 Levings MK, Sangregorio R, Roncarolo MG (2001) Human Cd25+ Cd4+ T Regulatory cells suppress naive and memory T Cell Proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295–1302
12.
Zurück zum Zitat Baratelli F, Lin Y, Zhu L et al (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175:1483–1490PubMed Baratelli F, Lin Y, Zhu L et al (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175:1483–1490PubMed
13.
Zurück zum Zitat Kohm AP, McMahon JS, Podojil JR et al (2006) Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 176:3301–3305PubMed Kohm AP, McMahon JS, Podojil JR et al (2006) Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 176:3301–3305PubMed
14.
Zurück zum Zitat Couper KN, Blount DG, De Souza JB, Suffia I, Belkaid Y, Riley EM (2007) Incomplete Depletion and Rapid Regeneration of Foxp3+ Regulatory T Cells Following Anti-CD25 Treatment in Malaria-Infected Mice. J Immunol 178:4136–4146PubMed Couper KN, Blount DG, De Souza JB, Suffia I, Belkaid Y, Riley EM (2007) Incomplete Depletion and Rapid Regeneration of Foxp3+ Regulatory T Cells Following Anti-CD25 Treatment in Malaria-Infected Mice. J Immunol 178:4136–4146PubMed
15.
Zurück zum Zitat Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59(13):3128–3133 Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59(13):3128–3133
16.
Zurück zum Zitat Nabors GS, Nolan T, Croop W, Li J, Farrell JP (1995) The influence of the site of parasite inoculation on the development of Th1 and Th2 type immune responses in (BALB/c x C57BL/6) F1 mice infected with Leishmania major. Parasite Immunol 17(11):569–579PubMedCrossRef Nabors GS, Nolan T, Croop W, Li J, Farrell JP (1995) The influence of the site of parasite inoculation on the development of Th1 and Th2 type immune responses in (BALB/c x C57BL/6) F1 mice infected with Leishmania major. Parasite Immunol 17(11):569–579PubMedCrossRef
17.
Zurück zum Zitat Chen X, Oppenheim JJ, Howard OM (2005) BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol 78(1):114–121. (Epub 2005 Apr 21) Chen X, Oppenheim JJ, Howard OM (2005) BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol 78(1):114–121. (Epub 2005 Apr 21)
18.
Zurück zum Zitat Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 66(8):4488–4495 Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 66(8):4488–4495
19.
Zurück zum Zitat Qin Z, Richter G, Schüler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4(5):627–630PubMedCrossRef Qin Z, Richter G, Schüler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4(5):627–630PubMedCrossRef
20.
Zurück zum Zitat Mizoguchi A, Bhan AK (2006) A case for regulatory B cells. J Immunol 176: 705–710 Mizoguchi A, Bhan AK (2006) A case for regulatory B cells. J Immunol 176: 705–710
21.
Zurück zum Zitat Yanaba K, Bouaziz JD, Haas KM et al (2008) Regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. JI 28(5);639-650 Yanaba K, Bouaziz JD, Haas KM et al (2008) Regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. JI 28(5);639-650
22.
Zurück zum Zitat Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 182(12):7459–7472 Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 182(12):7459–7472
23.
Zurück zum Zitat Lemoine S, Morva A, Youinou P, Jamin C (2009) Regulatory B cells in autoimmune diseases: how do they work? Ann N Y Acad Sci 1173:260–267PubMedCrossRef Lemoine S, Morva A, Youinou P, Jamin C (2009) Regulatory B cells in autoimmune diseases: how do they work? Ann N Y Acad Sci 1173:260–267PubMedCrossRef
24.
Zurück zum Zitat Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of Regulatory T Cells in the Peripheral Blood of Cancer Patients. Clin Cancer Res 9:606–612 Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of Regulatory T Cells in the Peripheral Blood of Cancer Patients. Clin Cancer Res 9:606–612
25.
Zurück zum Zitat Kretschmer K, Apostolou I, Jaeckel E, Khazaie K, von Boehmer H (2006) Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev 212:163–169 (Review) Kretschmer K, Apostolou I, Jaeckel E, Khazaie K, von Boehmer H (2006) Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev 212:163–169 (Review)
26.
Zurück zum Zitat Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106PubMedCrossRef Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106PubMedCrossRef
27.
Zurück zum Zitat Kim S, Fridlender ZG, Dunn R et al (2008) B cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models J Immunother 31(5):446–457 Kim S, Fridlender ZG, Dunn R et al (2008) B cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models J Immunother 31(5):446–457
28.
Zurück zum Zitat Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, Demengeot J (2005) Foxp3+CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci USA 102(11):4091–4096. (Epub 2005 Mar 7) Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, Demengeot J (2005) Foxp3+CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci USA 102(11):4091–4096. (Epub 2005 Mar 7)
29.
Zurück zum Zitat Suto A, Nakajima H, Ikeda K et al (2002) CD4+CD25+ T-cell development is regulated by at least 2 distinct mechanisms. Blood 99:555–560 No. 2PubMedCrossRef Suto A, Nakajima H, Ikeda K et al (2002) CD4+CD25+ T-cell development is regulated by at least 2 distinct mechanisms. Blood 99:555–560 No. 2PubMedCrossRef
30.
Zurück zum Zitat Molina A (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med 59:237–250. (Review) Molina A (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med 59:237–250. (Review)
31.
Zurück zum Zitat Mease PJ (2008) B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 35(7):1245–1255. (Review) Mease PJ (2008) B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 35(7):1245–1255. (Review)
32.
Zurück zum Zitat Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA (2005) Functional defects, the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes 54(5):1407–1414PubMedCrossRef Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA (2005) Functional defects, the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes 54(5):1407–1414PubMedCrossRef
33.
Zurück zum Zitat Chen J, Schmidtt A, Ginnopoulos K et al (2007) Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 31:1133–1139PubMed Chen J, Schmidtt A, Ginnopoulos K et al (2007) Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 31:1133–1139PubMed
34.
Zurück zum Zitat Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with Rituximab Blood 112(4):1147–1150. (Epub 2008 Mar 28) Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with Rituximab Blood 112(4):1147–1150. (Epub 2008 Mar 28)
35.
Zurück zum Zitat Stasi R, Del Poeta G, Stipa E et al (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110(8):2924–2930 Stasi R, Del Poeta G, Stipa E et al (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110(8):2924–2930
36.
Zurück zum Zitat Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R (1998) Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 161(12):6977–6984 Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R (1998) Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 161(12):6977–6984
37.
Zurück zum Zitat Perricone MA, Smith KA, Claussen KA et al (2004) Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27(4):273–281 Perricone MA, Smith KA, Claussen KA et al (2004) Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27(4):273–281
38.
Zurück zum Zitat Aklilu M, Stadler WM, Markiewicz M et al (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15(7):1109–1114 Aklilu M, Stadler WM, Markiewicz M et al (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15(7):1109–1114
39.
Zurück zum Zitat Barbera-Guillem E, Nelson MB, Barr B et al (2000) B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48(10):541–549 Barbera-Guillem E, Nelson MB, Barr B et al (2000) B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48(10):541–549
Metadaten
Titel
The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model
verfasst von
Tamar Tadmor
Yu Zhang
Hyun-Mi Cho
Eckhard R. Podack
Joseph D. Rosenblatt
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 5/2011
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-0972-z

Weitere Artikel der Ausgabe 5/2011

Cancer Immunology, Immunotherapy 5/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.